Retatrutide half-life is about 6 days, which supports once-weekly dosing. Learn what that means for steady state, washout, and half-life calculators.
Retatrutide has an average half-life of about 6 days, or roughly 144 hours, based on pharmacokinetic data reported from its early clinical trials. That long half-life is the main reason retatrutide is given as a once-weekly injection in research studies. Retatrutide is still an investigational drug and is not approved by the FDA for any use in the United States.
What Is Retatrutide?
Retatrutide is an experimental triple receptor agonist developed by Eli Lilly. It activates three hormone receptors at once: GIP, GLP-1, and glucagon.
That triple action is what separates it from older single-agonist and dual-agonist drugs. Researchers are studying it for obesity and type 2 diabetes in the Phase 3 TRIUMPH clinical program.
Because the molecule is still in trials, most of what is known about retatrutide half life comes from Phase 1 and Phase 2 pharmacokinetic reports rather than a finished FDA label. Published numbers can be updated as more data are collected.
How Long Is the Half-Life of Retatrutide?
Reported estimates cluster around 5.5 to 6.5 days, with roughly 6 days used as the working average. That places retatrutide in the same broad range as other weekly incretin-based injectables.
What "half-life" actually means
A half-life is the time it takes for the body to clear half of a drug from the bloodstream. Start with 100 units in the body, and about 50 remain after one half-life, 25 after two, and 12.5 after three.
Half-life is not the same as "how long the drug works." Effects depend on receptor activity and downstream biology, and those effects can outlast the drug's measurable presence in plasma.
| Compound | Approximate half-life | Typical dosing interval | FDA status |
|---|---|---|---|
| Retatrutide | About 6 days | Once weekly (in trials) | Investigational |
| Tirzepatide | About 5 days | Once weekly | Approved |
| Semaglutide | About 7 days | Once weekly | Approved |
| Cagrilintide | About 7 to 8 days | Once weekly (in trials) | Investigational |
Those figures are population averages. Any single person's numbers can land above or below the average for reasons described below.
Why a 6-Day Half-Life Supports Once-Weekly Dosing
With a 6-day half-life, a single dose still leaves a meaningful amount of drug in the body after a full week. A simplified timeline looks like this:
- Day 0: dose administered, peak exposure begins.
- Day 6: roughly 50% of that dose remains.
- Day 12: roughly 25% remains.
- Day 18: roughly 12.5% remains.
When a new injection arrives every 7 days, it lands before the previous dose is fully cleared. Drug levels therefore build up over the first several weeks.
Steady state is generally reached after about 4 to 5 half-lives. For retatrutide, that works out to roughly 4 to 5 weeks of weekly dosing, which matches the accumulation patterns described in trial data.
How Long Does Retatrutide Stay in Your System?
Using the five-half-life rule of thumb, near-complete elimination takes about 30 days after the last injection. Low residual amounts may be detectable somewhat longer, and individual clearance varies.
Appetite and blood sugar effects often fade sooner than the drug fully clears, because receptor signaling changes before plasma levels reach zero. That gap is one reason tapering decisions are best handled by a clinician.
If someone stops retatrutide and switches to another agent, a washout period of roughly 4 to 6 weeks is sometimes discussed in research settings. Anyone comparing weekly injectables should also look at the tirzepatide half-life and the cagrilintide half-life, since both follow similar once-weekly logic.
Retatrutide Half-Life Calculator: What It Can and Can't Do
A retatrutide half life calculator estimates how much drug remains in the body at a given point after a dose. Most calculators apply a simple exponential decay model using one average half-life.
These tools can be useful for:
- Visualizing how doses stack up week over week.
- Estimating when steady state is likely to be reached.
- Roughly timing a washout before starting another medication.
They cannot tell you your actual blood levels, predict whether you will get side effects, or replace a prescriber's dosing judgment. Real pharmacokinetics involves absorption rates, body composition, and organ function that a calculator does not capture.
Factors That Can Change a Drug's Half-Life
Half-life values come from group averages, and several factors can push an individual above or below that average:
- Kidney or liver function: Both organs help clear peptide drugs, so impairment can slow elimination.
- Body weight and composition: Larger body mass can change how a drug distributes and clears.
- Age: Clearance often slows with age.
- Injection site and technique: Absorption can vary slightly between sites.
- Immune response: Anti-drug antibodies can alter how long a biologic stays active.
It also helps to keep some perspective on the range across this drug class. The half-lives of weekly incretins are measured in days, while smaller peptides are measured in minutes or hours. By comparison, the aod 9604 half-life and the somatropin half-life are both only a few hours, which is why those compounds are dosed very differently.
Safety and Legal Status
Retatrutide is not approved by the FDA, is not available through US pharmacies, and cannot be legally prescribed. Products marketed online as "retatrutide" are unregulated, and their identity, purity, and sterility are not verified.
In clinical trials, the most common side effects were gastrointestinal: nausea, vomiting, diarrhea, and constipation. Investigators also tracked heart rate changes, gallbladder events, and injection site reactions.
Anyone considering a GLP-1, GIP, or glucagon-based medication should talk with a licensed healthcare professional about approved options, personal risk factors, and monitoring. This article is for general information only and is not medical advice.
Frequently Asked Questions
How long does retatrutide stay in your system?
Retatrutide has an average half-life of about 6 days, so it takes roughly 30 days (about five half-lives) for the drug to be nearly eliminated after a final dose. Small residual amounts may remain detectable a bit longer. Individual clearance varies with kidney and liver function, body weight, and age.
Is retatrutide FDA-approved?
No. Retatrutide is an investigational drug and is not approved by the FDA for any indication in the United States. It is currently being evaluated in Phase 3 trials for obesity and type 2 diabetes, and it is not available through licensed US pharmacies.
How does retatrutide's half-life compare to tirzepatide and semaglutide?
Retatrutide's half-life is about 6 days, tirzepatide's is about 5 days, and semaglutide's is about 7 days. All three fall into the same range that supports once-weekly dosing. Exact values differ between studies and between individual patients.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.